scm logo

SCM Lifescience, Inc. was selected as a business forum at Bio Korea 2022,

which will be Korea's representative bio-health international convention in which world-class scholars and corporate experts participate and had a place to present the company's R&D strategy and clinical progress through Bio-Live.

In addition, during the three days of the event, meetings were held with several participating companies and organizations through the 'Partnering' program.

On May 11th, Managing Director Seok-Jo Kim of Research & Business Innovative Development Division (hereinafter referred to as the Innovation Headquarters) 

‘Progress and application of R&D using stem cells in the treatment of intractable diseases’ was presented.

In this presentation, we also introduced the importance of the high-purity of stem cells in the commercialization process and the superiority of the Subfractionation Culturing Method,

the original technology of SCM Lifescience that can isolate and culture high-purity stem cells.

We also had meetings with nine companies and organizations that requested meetings in the "Partnering" program, including Parma, Biotechnology, Agencies, and Australian/Canadian/Israel Bio participants. Through this meeting, it was confirmed that Global Pharma, Biotech, and overseas R&D foundations are putting priority on whether to have original technologies that have become global rights.

Meeting partners showed great interest in stem cell separation and culture, the source technology of SCM Lifescience, Inc., which confirmed the possibility of strategic alliances to review mutual research pipelines and exchange commercialization models, rather than simply discovering business opportunities.

SCM Lifescience, Inc. Innovation Headquarters will continue to participate in various side events to secure the possibility of strategic alliances by presenting the excellence of original technology and various business models.